FI107880B - Förfarande för framställning av vaccin avsett att lindra symptomen vid eller förhindra uppkomsten av IgE-medierade allergiska reaktioner - Google Patents
Förfarande för framställning av vaccin avsett att lindra symptomen vid eller förhindra uppkomsten av IgE-medierade allergiska reaktioner Download PDFInfo
- Publication number
- FI107880B FI107880B FI941193A FI941193A FI107880B FI 107880 B FI107880 B FI 107880B FI 941193 A FI941193 A FI 941193A FI 941193 A FI941193 A FI 941193A FI 107880 B FI107880 B FI 107880B
- Authority
- FI
- Finland
- Prior art keywords
- ige
- vaccine
- protein
- antibodies
- rat
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 44
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 20
- 230000001404 mediated effect Effects 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 31
- 208000024891 symptom Diseases 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 26
- 239000002671 adjuvant Substances 0.000 claims abstract description 17
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 16
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 16
- 230000003053 immunization Effects 0.000 claims description 24
- 238000002649 immunization Methods 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 241000143940 Colias Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 15
- 102000036639 antigens Human genes 0.000 abstract description 15
- 108091007433 antigens Proteins 0.000 abstract description 15
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 14
- 210000003630 histaminocyte Anatomy 0.000 abstract description 13
- 208000026935 allergic disease Diseases 0.000 abstract description 9
- 230000007815 allergy Effects 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 5
- 210000003912 basophilic leucocyte Anatomy 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 239000013566 allergen Substances 0.000 abstract description 2
- 230000001419 dependent effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 67
- 230000028993 immune response Effects 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 241000894007 species Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 102000009438 IgE Receptors Human genes 0.000 description 11
- 108010073816 IgE Receptors Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 230000005875 antibody response Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108020005719 Species specific proteins Proteins 0.000 description 4
- 102000007397 Species specific proteins Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000016178 immune complex formation Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 241000522641 Senna Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000018981 granulocyte chemotaxis Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (2)
1. Förfarande för framställning av ett vaccin, vilket vaccin är avsett att lindra symptomen vid eller förhindra uppkomsten av IgE-medierade allergiska reaktioner hos ett däggdjur, kännetecknat därav, att genora kloning av cDNA- 5 sekvensen för axninosyrasekvensen av ifrägavarande däggdjurens IgE-epsilon-kedjans hela CH2-CH3-domän eller en sädan strukturell stahi1 enhet innehällande mer än 12 aminosyror därav,att man efter immunisering erhäller ett polyklonat svar, sä att flera olika antikroppar, riktade 10 mot olika epitoper inom CH2-CH3-regionen, kan samtidigt binda tili sarama IgE-antikropp och den nämnda domänen eller dess nämnda region ligeras i en lämplig vektor, vektorn transformeras in i en eukaryotisk eller prokaryotisk värdcell för produktion av ett fusionsprotein, som 15 innehäller hela CH2-CH3-domänen eller en strukturellt stabil region därav i sin ursprungliga eller en lätt muterad form, varvid proteinet är kopplat tili ett eller flera heterologa bärarproteiner, och det erhällna • fusionsproteinet renas och eventuellt isoleras, samt « · \.I 20 eventuellt blandas med ett lämpligt adjuvans. • · · • « ·
1. Menetelmä rokotteen valmistamiseksi, joka rokote on tarkoitettu lievittämään IgE-välitteisten yliherkkyysreaktioiden oireita nisäkkäässä tai estämään niitä, tunnettu siitä, että kloonaamalla kyseisen nisäkkään IgE:n 5 epsilonketjun koko CH2-CH3-alueen tai sen sellaisen rakenteellisesti stabiilin yli 12 aminohappoa käsittävän osan, jolla saavutetaan immunisaation jälkeen polyklonaalinen vaste, aminohappoketjua koodaava cDNA-sekvenssi, niin että useat eri vasta-aineet, jotka 10 kohdistuvat eri CH2-CH3-alueen epitooppeihin voivat samanaikaisesti sitoutua samaan IgE vasta-aineeseen ja mainittu alue tai sen mainittu osa ligoidaan sopivaan vektoriin, vektori transformoidaan eukaryoottiseen tai prokaryoottiseen isäntäsoluun sellaisen fuusioproteiinin 15 tuottamiseksi, jossa on koko CH2-CH3-alue tai sen rakenteellisesti stabiili osa alkuperäisessä muodossa tai muodossa, jossa on vain vähän mutaatioita, jolloin proteiini liittyy yhteen tai useampaan heterologiseen kantajaproteiiniin ja saatu fuusioproteiini puhdistetaan ja 20 haluttaessa eristetään, sekä haluttaessa sekoitetaan .. sopivan adjuvantin kanssa. • · ··« « · « ** 2. Patenttivaatimuksen 1 mukainen menetelmä, tunnettu siitä, että isäntäsoluna vektorin transformaatioon käyte- • 1 25 tään bakteerilajia, edullisesti Escherichia colia. e·· ··♦· • i· • · · • · · e • · ··· • · ··· • · • · m • e · ··♦ · ··« • · • · ··· • · · 27 107880 *
2. Förfarande enligt krav 1, kännetecknat därav, att man som värd för trans formering av vektorn använder en bakteriestam, företrädesvis Escherichia coli. ··· • · ♦ ♦ ♦ · 25 ♦ · ··· ··♦ • · • · · • ♦ ♦ ·♦♦ « • ·· • . · • · 1 • · · «
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9102808 | 1991-09-26 | ||
| SE9102808A SE9102808L (sv) | 1991-09-26 | 1991-09-26 | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| PCT/SE1992/000673 WO1993005810A1 (en) | 1991-09-26 | 1992-09-25 | VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS |
| SE9200673 | 1992-09-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI941193A0 FI941193A0 (sv) | 1994-03-14 |
| FI941193A FI941193A (sv) | 1994-03-14 |
| FI107880B true FI107880B (sv) | 2001-10-31 |
Family
ID=20383848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI941193A FI107880B (sv) | 1991-09-26 | 1994-03-14 | Förfarande för framställning av vaccin avsett att lindra symptomen vid eller förhindra uppkomsten av IgE-medierade allergiska reaktioner |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5653980A (sv) |
| EP (1) | EP0666760B2 (sv) |
| JP (2) | JP3583421B2 (sv) |
| KR (1) | KR100263359B1 (sv) |
| AT (1) | ATE189960T1 (sv) |
| AU (1) | AU677573B2 (sv) |
| CA (1) | CA2117193C (sv) |
| DE (1) | DE69230733T3 (sv) |
| DK (1) | DK0666760T4 (sv) |
| ES (1) | ES2144424T5 (sv) |
| FI (1) | FI107880B (sv) |
| GR (1) | GR3033272T3 (sv) |
| HU (1) | HU218899B (sv) |
| RU (1) | RU2120805C1 (sv) |
| SE (1) | SE9102808L (sv) |
| WO (1) | WO1993005810A1 (sv) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU707083B2 (en) * | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| AP660A (en) * | 1994-01-18 | 1998-08-18 | Genentech Inc | A method of treatment of parasitic infection using IgE antagonists. |
| FR2715304B1 (fr) * | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
| SK284856B6 (sk) | 1996-03-01 | 2006-01-05 | Novartis Ag | Imunogénna molekula, farmaceutická kompozícia, ligand, spôsob prípravy imunogénnej molekuly a jej použitie |
| CA2289476A1 (en) * | 1997-04-15 | 1998-10-22 | Farmaceutisk Laboratorium Ferring A/S | Modified tnf.alpha. molecules, dna encoding such modified tnf.alpha. molecules and vaccines comprising such modified tnf.alpha. molecules and dna |
| US6504013B1 (en) | 2000-02-01 | 2003-01-07 | Idexx Laboratories, Inc. | Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody |
| US7393529B2 (en) * | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
| US6734287B1 (en) | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
| US6913749B2 (en) * | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| EP1621209A3 (en) * | 1998-11-02 | 2006-04-19 | Resistentia Pharmaceuticals AB | Vaccines based on domains of chimeric immunoglobulin E peptides |
| US6602719B1 (en) | 1999-03-26 | 2003-08-05 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
| US6511814B1 (en) | 1999-03-26 | 2003-01-28 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
| EP2361635A3 (en) * | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| JP2003047482A (ja) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性ＩｇＥワクチン |
| AU2002326751A1 (en) * | 2001-08-13 | 2003-03-03 | Ige Therapeutics, Inc. | Immunoglobulin e vaccines and methods of use thereof |
| AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
| CA2497660A1 (en) * | 2002-09-05 | 2004-03-18 | Resistentia Pharmaceuticals Ab | Allergy vaccines |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| JP5764290B2 (ja) | 2006-06-26 | 2015-08-19 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体およびその使用法 |
| US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
| BRPI0922561A2 (pt) | 2008-12-09 | 2020-08-11 | Pfizer Vaccines Llc | vacina de peptídeo de ch3 da ige. |
| EP2401300B1 (en) * | 2009-02-25 | 2018-01-10 | Academia Sinica | ANTI-C[epsilon]mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES |
| EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| WO2013158274A1 (en) | 2012-04-20 | 2013-10-24 | Academia Sinica | ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS |
| EP2862873B1 (en) * | 2012-06-18 | 2020-04-29 | Nippon Zenyaku Kogyo Co., Ltd. | IgE PEPTIDE VACCINE |
| WO2015002985A2 (en) * | 2013-07-01 | 2015-01-08 | University Of Maryland | Fc coupled compositions and methods of their use |
| BR112020008488A2 (pt) | 2017-10-31 | 2020-10-20 | Oneness Biotech Co. Ltd. | tratamento de doenças alérgicas mediadas por ige |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8616166D0 (en) * | 1986-07-02 | 1986-08-06 | Research Corp Ltd | Polypeptide competitor |
| GB8727045D0 (en) * | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
| DE3853636T3 (de) * | 1987-12-31 | 1999-04-08 | Tanox Biosystems, Inc., Houston, Tex. | Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden. |
| GB8910263D0 (en) * | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
| GB8913737D0 (en) * | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
-
1991
- 1991-09-26 SE SE9102808A patent/SE9102808L/sv not_active Application Discontinuation
-
1992
- 1992-09-25 US US08/196,227 patent/US5653980A/en not_active Expired - Lifetime
- 1992-09-25 AT AT92920757T patent/ATE189960T1/de not_active IP Right Cessation
- 1992-09-25 HU HU9400845A patent/HU218899B/hu not_active IP Right Cessation
- 1992-09-25 JP JP50558293A patent/JP3583421B2/ja not_active Expired - Fee Related
- 1992-09-25 ES ES92920757T patent/ES2144424T5/es not_active Expired - Lifetime
- 1992-09-25 KR KR1019940700753A patent/KR100263359B1/ko not_active IP Right Cessation
- 1992-09-25 EP EP92920757A patent/EP0666760B2/en not_active Expired - Lifetime
- 1992-09-25 DE DE69230733T patent/DE69230733T3/de not_active Expired - Fee Related
- 1992-09-25 DK DK92920757T patent/DK0666760T4/da active
- 1992-09-25 CA CA002117193A patent/CA2117193C/en not_active Expired - Fee Related
- 1992-09-25 RU RU94020409A patent/RU2120805C1/ru not_active IP Right Cessation
- 1992-09-25 AU AU26765/92A patent/AU677573B2/en not_active Ceased
- 1992-09-25 WO PCT/SE1992/000673 patent/WO1993005810A1/en active IP Right Grant
-
1994
- 1994-03-14 FI FI941193A patent/FI107880B/sv active
-
2000
- 2000-04-19 GR GR20000400955T patent/GR3033272T3/el unknown
-
2004
- 2004-03-23 JP JP2004084530A patent/JP2004231663A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69230733D1 (de) | 2000-04-06 |
| HUT69782A (en) | 1995-09-28 |
| SE9102808L (sv) | 1993-03-27 |
| JP3583421B2 (ja) | 2004-11-04 |
| EP0666760A1 (en) | 1995-08-16 |
| KR100263359B1 (ko) | 2000-08-01 |
| RU2120805C1 (ru) | 1998-10-27 |
| GR3033272T3 (en) | 2000-09-29 |
| EP0666760B2 (en) | 2007-10-10 |
| FI941193A0 (sv) | 1994-03-14 |
| DK0666760T3 (da) | 2000-07-31 |
| JP2004231663A (ja) | 2004-08-19 |
| CA2117193A1 (en) | 1993-04-01 |
| HU218899B (hu) | 2000-12-28 |
| US5653980A (en) | 1997-08-05 |
| ES2144424T5 (es) | 2008-03-01 |
| SE9102808D0 (sv) | 1991-09-26 |
| WO1993005810A1 (en) | 1993-04-01 |
| ES2144424T3 (es) | 2000-06-16 |
| ATE189960T1 (de) | 2000-03-15 |
| AU677573B2 (en) | 1997-05-01 |
| JPH06510768A (ja) | 1994-12-01 |
| FI941193A (sv) | 1994-03-14 |
| HU9400845D0 (en) | 1994-06-28 |
| DE69230733T2 (de) | 2000-08-03 |
| AU2676592A (en) | 1993-04-27 |
| CA2117193C (en) | 2008-06-17 |
| DK0666760T4 (da) | 2008-01-21 |
| EP0666760B1 (en) | 2000-03-01 |
| DE69230733T3 (de) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI107880B (sv) | Förfarande för framställning av vaccin avsett att lindra symptomen vid eller förhindra uppkomsten av IgE-medierade allergiska reaktioner | |
| US4093606A (en) | Method of producing intravenously injectable gamma globulin and a gamma globulin suitable for carrying out the method | |
| US9409996B2 (en) | Treatment of food intolerance and food allergy with IgM | |
| US4165370A (en) | Injectable gamma globulin | |
| JP4031201B2 (ja) | アレルギー治療用免疫原としてのペプチド組成物 | |
| KR100584051B1 (ko) | 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐 | |
| FI110615B (sv) | Förfarande för tillverkning av protein som bildar en modifierad kapsid | |
| EP0403312A1 (en) | Immunoactive peptides and antibodies and their use in anti-allergy treatment | |
| JPS61501705A (ja) | Ｔ細胞及びｂ細胞決定基の両者を含む合成ｂ型肝炎ウイルスワクチン | |
| JP2633881B2 (ja) | 免疫調節組成物及びそれらの使用 | |
| JP2003137897A (ja) | 可溶性組換えボツリヌス毒素タンパク | |
| AU657915B2 (en) | Transfer factor and methods of use | |
| US8313730B2 (en) | Treatment of celiac disease with IgA | |
| NZ511079A (en) | Immunogenic polypeptide comprising a self IgE portion and a non-self IgE portion, wherein the said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal | |
| US8119104B2 (en) | Treatment of celiac disease with IgA | |
| JPH10509038A (ja) | 免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製 | |
| US4297343A (en) | Contraceptive agent | |
| JP2001518451A (ja) | アレルゲンの非アナフィラキシー形およびその使用 | |
| Strannegård | Regulatory effects of antigen and antibody on the reagin response in rabbits | |
| ES2256579T3 (es) | Anticuerpos que estimulan la produccion de 1l-1ra. | |
| NO319856B1 (no) | Vaksine for a lindre symptomene ved, eller forhindre inntreden av,IgE-formidlede,allergiske reaksjoner hos et pattedyr,samt anvendelse av aminosyresekvensen fra de konstante CH2-CH3-domener i epsilonkjeden for fremstilling av en vaksine mot IgE-formidlede allergiske reaksjoner. | |
| EP1621209A2 (en) | Vaccines based on domains of chimeric immunoglobulin E peptides |